Search results
Discover how vaccines save millions of lives annually, offering protection against many infectious diseases. Read about the range of Sanofi vaccines available. Every year, vaccination saves up to 5 million lives worldwide.
Sanofi has been a leader in vaccines for over 100 years: the combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did. Our determination to improve public health motivates us to develop new vaccines to address still unmet medical needs.
Jul 25, 2024 · Our determination to find answers for patients and their families motivates us to pursue medicines and vaccines with the greatest potential to improve lives and protect public health. With a strong focus on difficult-to-treat diseases and immunization, our R&D pipeline includes 78 clinical-stage projects, 33 of which are in phase 3 ...
Vaccination is one of the most important things we can do to protect ourselves and our children from vaccine preventable illness. 4,5. However, vaccines also work at the community level. Some people can't be vaccinated, either because they are too young or because their immune system is weak.
Nov 10, 2015 · About VidPrevtyn Beta VidPrevtyn Beta is a monovalent, recombinant-protein next-generation COVID-19 vaccine developed by Sanofi, modelled on the Beta variant and including GSK’s pandemic adjuvant. The same recombinant-protein technology is used in Sanofi’s approved seasonal flu vaccines.
At Sanofi, our vaccine R&D is driving innovation, focusing on solutions that push global health forward. Learn about our research areas. Global pharmaceutical and healthcare company Sanofi's teams are developing vaccines with the greatest potential to fight infectious diseases.
May 10, 2006 · Starting in 2025, Sanofi will book sales of Novavax’s adjuvanted COVID-19 vaccine and will support certain R&D, regulatory, and commercial expenses. Novavax will receive tiered double-digit percentage royalty payments on sales by Sanofi of COVID-19 vaccines and flu-COVID-19 combination vaccines.
We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.
Sep 28, 2006 · Targeting 2022 initiation of its clinical studies for an influenza vaccine with modified mRNA, Sanofi launched a Phase 1 clinical trial in June 2021 evaluating an mRNA-based investigational vaccine against seasonal influenza.
Sanofi has been a leader in vaccines for over 100 years. The combination of our innovative vaccines and global reach means that many diseases do not hold the power they once did. Our determination to improve public health motivates us to de-velop new vaccines to address still unmet medical needs. Fueled
